April 2017 Digital Edition
March 2017 Digital Edition
Feb. 2017 Digital Edition
January 2017 Digital Edition
Nov/Dec 2016 Digital Edition
Oct 2016 Digital Edition
Inovio appoints vaccines, bioterror expert to its board
Dr. Adel Mahmoud
Inovio Pharmaceuticals, Inc. appointed Dr. Adel Mahmoud, a global infectious disease, vaccines and bioterrorism expert, to its board of directors on March 27.
During a long tenure at Merck & Co., Mahmoud was responsible for the development and commercialization of several new important vaccines, including Gardasil, Zostavax, Proquad and Rotateq, said Inovio. He retired from Merck in 2005.
Mahmoud is currently professor, Department of Molecular Biology and the Woodrow Wilson School of Public and International Affairs at Princeton University. He was president of Merck Vaccines from 1999 to 2005 and served as that company’s chief medical advisor for vaccines and infectious diseases, said Inovio.
More recently, Mahmoud has been leading strategy development efforts for global health agencies tackling bioterrorism and emerging diseases such as pandemic influenza and SARS. Prior to joining Merck, Mahmoud was chairman, Department of Medicine and Physician-in-Chief (1987-1998) at Case Western Reserve University School of Medicine and University Hospitals of Cleveland.
"I am pleased to join the medical and business leaders on Inovio's Board at a time when Inovio's synthetic vaccine technology is achieving important evidence of its potential and its avenues for product development and advancement represent an array of notable opportunities and choices," said Mahmoud in a statement on March 27.
"Dr. Mahmoud is known throughout the industry for his success in gaining approval for several blockbuster vaccines,” said Dr. J. Joseph Kim, President and chief executive officer at Inovio said. “His insights will be advantageous to Inovio as we move our synthetic vaccine portfolio toward late-stage clinical trials."